Imaging Findings in Children Presenting with CNS Nelarabine Toxicity

AJNR Am J Neuroradiol. 2022 Dec;43(12):1802-1809. doi: 10.3174/ajnr.A7692. Epub 2022 Nov 3.

Abstract

Nelarabine is a nucleoside analog critical for the treatment of patients with T-cell acute lymphoblastic leukemia/lymphoma. However, clinical peripheral and central neurologic adverse events associated with nelarabine administration have been reported. Neuroimaging of brain neurotoxicity has only been described in very few reports in pediatric patients so far. Six children with diagnosed T-cell acute lymphoblastic leukemia who clinically experienced possible, probable, or definite nelarabine-induced toxicity and underwent spine and/or brain MR imaging were reviewed. Neuroimaging findings showed a mixture of patterns including features of acute toxic leukoencephalopathy (seen in 6 cases), posterior reversible encephalopathy syndrome (2 cases), involvement of deep gray structures (1 case) and brainstem (2 cases), cranial and spinal neuropathy (2 cases each), and myelopathy (2 cases). Even though neuroimaging findings are nonspecific, the goal of this article was to alert the pediatric neuroradiologists, radiologists, and clinicians about the possibility of nelarabine-induced neurotoxicity and its broad neuroimaging spectrum.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arabinonucleosides / adverse effects
  • Child
  • Humans
  • Posterior Leukoencephalopathy Syndrome*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Spinal Cord Diseases*

Substances

  • nelarabine
  • Arabinonucleosides